In conclusion, our findings show that IRF5 expression in tumor cells translates to the packaging of IRF5 mRNA in EVs, causing downstream effects of reduced metastatic burden and immune programming towards a more protective or anti-tumorigenic immune microenvironment. This evidence concerns the gene IRF5 and neoplasm.